Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals MENLO PARK, Calif., Nov. 2, 2023 /PRNewswire/ — MyOme, Inc….
Author: Ken Dropiewski
Empatica’s Platform Receives New FDA Clearance for Cardiac Digital Biomarkers
Powerful and comprehensive health monitoring platform now offers FDA-cleared biomarkers for pulse and respiratory rate BOSTON, Nov. 2, 2023 /PRNewswire/ — Empatica, a digital health and AI company developing medical-grade wearables and digital biomarkers for health monitoring and…
Silk Road Medical Names Chas McKhann Chief Executive Officer
Accomplished Leader with Over 25 Years of Medical Device Industry Experience SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the “Company”), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed […]
Volta Medical Named Best Startup at Prix Galien USA Awards 2023
Widely considered the industry’s highest accolade for life sciences research and development, the Prix Galien Awards honor innovative treatments and technologies that improve human health MARSEILLE, France, Nov. 02, 2023 (GLOBE NEWSWIRE) — Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in […]
FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platform
AUCKLAND, New Zealand–(BUSINESS WIRE)–Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology. The CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive evaluation for risk of cardiovascular disease (CVD) using fundus retinal image
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced results from a pooled analysis of DETOUR1 and DETOUR2 Studies evaluating Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System. PTAB with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral art
Sirona Announces Support for SpaceX’s Starlink Network, Allowing Radiologists to Practice from Anywhere
SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ — Sirona Medical, the leader in cloud-native radiology workflow software, today announces general support for SpaceX’s Starlink platform, allowing Sirona’s industry-leading performance from almost anywhere in the world. “One of the biggest…
Teleflex Announces Quarterly Dividend
WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2023, to shareholders of record at the close of business on […]
Teleflex Reports Third Quarter Financial Results and Full Year 2023 Outlook
WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023. Third quarter financial summary Revenues of $746.4 million, up 8.7% compared to the prior year period; up 7.4% on a constant currency basis GAAP diluted EPS […]
Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System
GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study. MARRS is a multi-center trial to evaluate the performance of the Millipede System. The first patient was enrolled at Stony Brook University Hospital in Stony Brook, NY. “I am delighted to begin enrollment in the MARR



